How Long Do Semaglutide and Tirzepatide Side Effects Last?

Where you are on the dose ladder predicts how you feel far better than how many weeks you have been treated. Both approved labels and both pivotal obesity trials put the nausea, vomiting and diarrhea in the escalation phase, not spread evenly across a year.^[1][3][5][6] The other half of the answer is pharmacokinetic and nobody mentions it: semaglutide's half-life runs to roughly seven days and tirzepatide's to roughly five, so an effect does not end when the injection wears off, because a weekly injection does not really wear off.^[1][4]

The clock that matters is the escalation clock

Both labels say the same thing in almost the same words, and it is the single most useful sentence in either document. Zepbound's prescribing information records that most of the nausea, the vomiting and the diarrhea arrived while the dose was being escalated, and eased as treatment went on.^[3] Wegovy's records that gastrointestinal reactions were most frequently reported during dosage escalation.^[1]

The trials say it too. In the 68-week semaglutide trial, nausea and diarrhea were described by the investigators as typically transient, mild to moderate, and subsiding with time.^[5] In the 72-week tirzepatide obesity trial, which built in a 20-week escalation period, the gastrointestinal events occurred primarily during that period.^[6] So a reader at week 30 on an unchanged dose and a reader at week 30 who moved up last Tuesday are asking different questions, even though both would type the same thing into a search box.

How wide is the beat? The labels give escalation intervals, and they are worth knowing as facts about the approved products rather than as anything to act on. Zepbound's label sets increases at 2.5 mg a step, with a floor of four weeks on the current dose before the next one.^[3] Wegovy's injection label titrates on the same four-week beat, and adds a provision people rarely hear about: where a dose is not tolerated on the way up, a prescriber may consider holding the escalation back by four weeks.^[1] That last clause is written for a prescriber. It is a description of what the label permits a clinician to do, and the way to use it is to raise tolerability at your next appointment.

How long a single dose is actually in you

This is where the intuition from ordinary medicines misleads people. A weekly GLP-1 injection is not a pill that clears overnight, and both labels put numbers on it.

Three consequences fall out of that table. A symptom that starts two days after an injection is not necessarily “from that shot” in any clean way, because the previous doses have not left. An effect that troubles you is unlikely to disappear the day after a missed injection. And if a dose has gone wrong, the labels themselves anticipate a period of observation measured in days rather than hours — which is why the answer to a bad reaction is a clinician who can watch it, not a timer.

It also explains a pattern people report and then doubt: feeling different for weeks after stopping. The Wegovy label's instruction to stop two months ahead of any planned pregnancy is an official acknowledgment that the drug lingers.^[1] Stopping, and when, is a conversation with a prescriber. If the reason you are considering it is that a program has ended or repriced, we walk through the options in what to do when a compounded GLP-1 program ends, and every seller we track carries a dated figure on the price tracker.

What usually settles, and what does not follow that shape

The gastrointestinal cluster is the part with a settling pattern behind it. Nausea, vomiting, diarrhea, constipation, reflux, burping and abdominal discomfort dominate both labels' adverse reaction sections, and both trials and both labels put them at their heaviest during escalation.^[1][3][5][6] Some people leave anyway: permanent discontinuation for a gastrointestinal reaction ran 4.3 percent against 0.7 percent on placebo in the Wegovy adult weight trials, and 4.5 percent against 0.8 percent in the semaglutide trial.^[1][5] Zepbound's label adds the timing of those exits — most of the people who stopped for an adverse reaction did so in the first few months.^[3]

Other effects do not behave like that at all, and one of them is documented with unusual honesty. Wegovy's label describes dysesthesia — altered skin sensation, tingling, burning, tenderness — reported by 22 percent of patients at the 7.2 mg dose against 6 percent at 2.4 mg and 0.3 percent on placebo. Among 288 patients who had it at the higher dose, 18 percent did not report recovering during the trial, and in most of those the dose was never changed. Of the patients who did recover after something was done and were then moved back up to 7.2 mg, 17 of 38 had it again.^[1]

That paragraph is doing something the marketing never does. It says an effect can persist, that not intervening was associated with not recovering, and that re-escalation brought it back in nearly half of those who tried. It is specific to one molecule at one dose and should not be generalized into a claim about the class. It should absolutely be generalized into a habit: an effect that is not settling is a reason to tell someone, not a reason to wait longer.

And a third category is not a duration question in the first place. Gallbladder disease, pancreatitis and kidney injury from dehydration are events with a labeled warning on both products.^[1][3] They do not have a typical timeline, because they are not the sort of thing you wait out.

The same-day list

These are drawn from the warnings and the patient information in the approved labels. They are not a diagnosis and they are not exhaustive. They are the symptoms whose whole point is that they should not be watched at home.

• Abdominal pain that is severe, or that will not go away, and that sometimes reaches through to the back. Nausea and vomiting may or may not come with it. Both labels use that picture to describe possible acute pancreatitis, and both direct that treatment stop where pancreatitis is suspected — a clinician's call, made the same day.^[1][3]
• Vomiting beyond about a day with nothing staying down, or the signs of dehydration. The labeled route to kidney injury on these drugs runs through volume depletion caused by vomiting or diarrhea, and postmarketing reports include cases needing hemodialysis.^[1][3]
• Pain high in the abdomen, a fever, skin or eyes turning yellow, or stools that have gone clay-colored. The Zepbound patient information lists exactly these as gallbladder symptoms to report right away.^[3]
• Swelling around the mouth, the tongue or the throat; difficulty breathing or swallowing; a severe rash; fainting. The label's instruction here is to stop and get medical help right away. Anaphylaxis and angioedema are both on the record as serious hypersensitivity reactions to this drug.^[3]
• Anything that arrived suddenly and is not easing on an unchanged dose. The pattern in the evidence is escalation-linked and improving. A symptom that does not fit the pattern is worth a call precisely because it does not fit.

Does it depend which drug you are on?

Less than the marketing implies, at least for the serious end of the gastrointestinal spectrum. A cohort study of routine practice in adults with type 2 diabetes matched new users of dulaglutide, subcutaneous semaglutide and tirzepatide into three pairwise comparisons — 65,238 matched pairs, 20,893 and 46,620 — and looked at a composite of acute pancreatitis, biliary disease, bowel obstruction, gastroparesis and severe constipation. The hazard ratios were 0.96, 0.96 and 1.07, with confidence intervals crossing 1 in every comparison.^[7]

The authors' own conclusion was that the three drugs have similar gastrointestinal safety profiles, and their own stated limitation was possible residual confounding by glycemic control and body mass index.^[7] It is a database study rather than a randomized comparison, and it covers severe events rather than everyday nausea. Within those limits, it is the best available answer to “would switching molecules fix this”, and the answer is that it might not.

If your vial was compounded, one variable is not fixed

Everything above assumes the amount you took is the amount your prescription says. With an approved pen that is a manufacturing guarantee. With a compounded vial the concentration is chosen by the pharmacy, so the volume that delivers a given dose is not standardized between suppliers, and FDA has reported adverse events, some requiring hospitalization, that may relate to patients measuring and self-administering incorrect doses of compounded semaglutide.^[8]

That matters here for one specific reason: an unexpectedly large dose and an ordinary dose produce symptoms from the same list, so “how long will this last” cannot be answered without knowing which one happened. Ask the pharmacy for the concentration in milligrams per milliliter and take the number to your prescriber. We take that problem apart in compounded tirzepatide side effects, the multi-year picture is in tirzepatide long-term side effects, and which pharmacy is behind a given program is recorded in our pharmacy register and on the compounded tirzepatide board.